Form 8-K · Current Report · Filed 2025-07-28
Metsera Reports Second Quarter 2025 Financial Results and Pipeline Update
Metsera, Inc. reported second-quarter 2025 financial results, showing a net loss of $68.7 million for the quarter and $145.3 million for the six months ended June 30, 2025. The company's cash position stood at $530.9 million as of June 30, 2025, which is expected to fund operations into 2027. Metsera also provided updates on its clinical pipeline, with positive Phase 1 data for its amylin candidate MET-233i and ongoing Phase 2b trials for its GLP-1 receptor agonist MET-097i.
- Filer
- MTSR MTSR
- Filed
- Accession
- 0000950170-25-099185
- CIK
- 0002040807
- Signal
- Low impact
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$40.47
Next session
-8.2%
Since filing
+74.2%
Latest close
$70.50
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from MTSR reporting the same item, with the next session's move:
Exhibits (1)
Never miss another MTSR filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.